ইঙ্গিত ও ব্যবহার
Interon এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Renal cell carcinoma: In an escalating dose of 3 million unit 3 times/week for 1 week, then 9 million unit 3 times/week for 1 week, then 18 million unit 3 times/week thereafter for 3-12 month.Chronic hepatitis B: 2.5-5 million unit/m2 3 times/week for 4-6 month. Chronic hepatitis C with ribavirin: 3-4.5 million unit 3 times/week for 6 month. Monotherapy: 3 million unit 3 times/ week for 12 month. Hairy cell leukaemia 3 million unit/day for 16-24 week. Maintenance: 3 million unit 3 times/week, up to 24 week.AIDS related Kaposi's sarcoma: In an escalating dose of 3 million unit/day for 3 days, 9 million unit/day for 3 days, 18 million unit/day for 3 days, and 36 million unit/day (if tolerated) on days 10-84. thereafter max tolerated dose (up to 36 million u) 3 times/week.Chronic myeloid leukaemia: In an escalating dose of 3 million unit/day for 3 days, 6 million unit/day for 3 days, and 9 million unit/day thereafter. For responders after 12 week: Continue treatment until haematological response is complete or up to 18 month. Follicular lymphoma As adjunct to chemotherapy: 6 million unit/m2/day on days 22-26 of each 28-day cycle.Cutaneous T-cell lymphoma: In an escalating dose of 3 million unit/day for 3 days, then 9 million unit/day for 3 days, and then 18 million unit/day to complete 12 week of treatment. Thereafter, max tolerated dose (up to 18 million unit) 3 times/week for at least 12 month in responders.Melanoma: 3 million unit 3 times/week for 18 month. Start treatment no later than 6 week after surgery.
পার্শ্বপ্রতিক্রিয়া
Depressive illness, suicidal behaviour, irritability, insomnia, anxiety. Flu-like symptoms. Headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. Gl disturbances. Dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. Inj site reaction, alopecia, rash, dry skin or pruritus. Conjunctivitis, menstrual irregularity, visual disturbances. Coughing, dyspnoea. Myalgia, joint or bone pain, arthritis or polyarthritis. Bone marrow depression.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
History of depression (monitor for signs). Perform regular neuropsychiatric monitoring. Seizure disorders and/or compromised CNS function. Preexisting or any history of cardiac disease. Monitor CBC prior to and during therapy. Myelosuppression or concurrent use of myelosuppressive drugs. Hypothyroidism, hyperthyroidism, DM. Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Monitor patients with impaired renal function.
নিষেধাজ্ঞা
Interferon Alfa-2a is contraindicated in patients with a history of hypersensitivity to recombinant interferon alfa-2a or any component of the preparation. patients with severe pre-existing cardiac disease or with any history of cardiac illness. No direct cardiotoxic effect has been demonstrated, but it is likely that acute, self-limiting toxicities (e.g. fever, chills) frequently associated with administration of Interferon Alfa-2a may exacerbate pre-existing cardiac conditions. severe renal, hepatic or myeloid dysfunction. seizure disorders and/or compromised central nervous system function. chronic hepatitis with advanced, decompensated hepatic disease. chronic hepatitis patients who are being or have recently been treated with immunosuppressive agents, excluding short-term "steroid withdrawal". CML patients with an HLA-identical relative who are potential candidates for allogeneic bone marrow transplantation in the immediate future. neonates, children up to 3 years, and premature infants. Interferon Alfa-2a solution for injection contains benzyl alcohol. There have been reports of permanent neuropsychiatric deficits and multiple system organ failure associated with benzyl alcohol.